Rechercher | DIAL.pr - BOREAL

Accès à distance ? S'identifier sur le proxy UCLouvain

Affichage: 2 résultats.

- Article de périodique
Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma.
Villa, Diego Hoster, Eva Hermine, Olivier Klapper, Wolfram Szymczyk, Michal Bosly, André[UCL] Unterhalt, Michael Rimsza, Lisa M Ramsower, Colleen Freeman, Ciara L Scott, David W Gerrie, Alina S Savage, Kerry J Sehn, Laurie H Dreyling, Martin (2022) Blood advances — Vol. 6, no. 18, p. 5285-5294 (2022)
- Article de périodique
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan, Asher Cramer, Paula Demirkan, Fatih Fraser, Graeme Silva, Rodrigo Santucci Grosicki, Sebastian Pristupa, Aleksander Janssens, Ann Mayer, Jiri Bartlett, Nancy L Dilhuydy, Marie-Sarah Pylypenko, Halyna Loscertales, Javier Avigdor, Abraham Rule, Simon Villa, Diego Samoilova, Olga Panagiotidis, Panagiots Goy, Andre Mato, Anthony HELIOS investigators Van Den Neste, Eric[UCL] (2016) The Lancet Oncology — Vol. 17, no. 2, p. 200-211 (2016)